GlassScriptPhysician profile
Jennifer K Morgan
NPI 1649262676
$683.34
in general payments reported to CMS, 2019-2025
16 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.37 · 2020: $23.49 · 2021: $28.95 · 2022: $62.47 · 2023: $107 · 2024: $156 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $470.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $222.67 | 2019-2025 | |
| Amgen INC. | $116.18 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Glaxosmithkline, LLC. | $46.38 | 2022-2025 | Zejula |
| Novartis Pharmaceuticals Corporation | $41.39 | 2024-2025 | |
| Celgene Corporation | $39.75 | 2024-2025 | Reblozyl |
| Sumitomo Pharma America, INC. | $37.01 | 2025 | Myfembree |
| Adaptive Biotechnologies Corporation | $31.75 | 2024 | Clonoseq |
| Daiichi Sankyo INC. | $29.80 | 2025 | Enhertu |
| Kite Pharma, INC. | $22.96 | 2025 | Yescarta |
| Karyopharm Therapeutics INC. | $17.03 | 2021 | |
| Abbvie INC. | $15.36 | 2024 | |
| Genzyme Corporation | $13.56 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $13.46 | 2023 | Epkinly |
| Eisai INC. | $12.55 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.